1. 5. Food and Drug Administration. FDA’s decision to approve new treatment for Alzheimer’s disease. Available at: www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease (accessed June 2021).
2. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future;Cummings;J Alzheimers Dis,2018
3. 6. Food and Drug Administration . Early Alzheimer’s Disease: Developing Drugs for Treatment Guidance for Industry. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER); 2018.
4. 11. Food and Drug Administration. Summary memorandum. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2021/Aducanumab_BLA761178_Dunn_2021_06_07.pdf (accessed June 2021).
5. 7. European Medicines Agency. Clinical investigation of medicines for the treatment of Alzheimer’s disease: CPMP/EWP/553/1995. Available at: www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf (accessed January 2021).